Form 4: NewAmsterdam Pharma CAO Sells Shares Under 10b5-1 Plan

NewAmsterdam Pharma's Chief Accounting Officer, Louise Frederika Kooij, reported the sale of 8,269 ordinary shares for approximately $24.86 per share.

Summary

• Louise Frederika Kooij, Chief Accounting Officer of NewAmsterdam Pharma Co N.V. (NAMS), reported the sale of 8,269 ordinary shares.
• The transaction occurred on August 25, 2025, at a weighted average price of $24.86 per share.
• The shares were sold in multiple transactions at prices ranging from $24.74 to $24.92 per share.
• Following the sale, Ms. Kooij directly beneficially owns 15,000 ordinary shares.
• The transaction was made pursuant to a Rule 10b5-1(c) pre-arranged trading plan.

Sentiment

Score: 4

Explanation: The sale of shares by a key executive, even under a 10b5-1 plan, generally indicates a slight negative sentiment as it reduces insider ownership. The future transaction date is unusual but doesn't change the underlying action of reducing stake.

Positives

• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-scheduled sale not based on immediate, non-public information.

Negatives

• An insider, specifically the Chief Accounting Officer, reduced their direct beneficial ownership in the company by selling 8,269 ordinary shares.

Risks

• Insider sales, even under a 10b5-1 plan, can sometimes be perceived by the market as a signal of reduced confidence or a lack of significant upside potential by management.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing reports an individual insider transaction and does not provide information relevant to broader industry trends or competitive landscape.

Related Party Transactions

• The sale of shares by the Chief Accounting Officer is considered a related party transaction due to the individual's executive position within the company.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a signal of reduced confidence, potentially leading to negative short-term price pressure.
• Employees: No direct impact mentioned, but could indirectly affect morale if perceived negatively.

Key Dates

Recommendation

While an insider sale by the Chief Accounting Officer is generally a negative signal, the execution under a Rule 10b5-1 plan mitigates the immediate concern that it's based on new, adverse non-public information. The remaining beneficial ownership of 15,000 shares indicates continued alignment. Without further company-specific news or broader market context, a 'hold' recommendation is appropriate, advising investors to monitor future developments rather than making an immediate 'sell' decision based solely on this transaction.

Keywords

NewAmsterdam Pharma, NAMS, Insider Sale, Form 4, Beneficial Ownership, Chief Accounting Officer, Equity Transaction, 10b5-1 Plan